1.
Open Forum Infect Dis
; 9(5): ofac157, 2022 May.
Article
in English
| MEDLINE
| ID: mdl-35493122
ABSTRACT
Shortening duration of direct-acting antiviral therapy for chronic hepatitis C could provide cost savings, reduce medication exposure, and foster adherence and treatment completion in special populations. The current analysis indicates that measuring hepatitis C virus at baseline and on days 7 and 14 of therapy can identify patients for shortening therapy duration.